Switch theme
Sign up to access all valuation multiples
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
1997
116
LTM Revenue $11.9M
LTM EBITDA -$28.2M
$164M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Heidelberg Pharma has a last 12-month revenue (LTM) of $11.9M and a last 12-month EBITDA of -$28.2M.
In the most recent fiscal year, Heidelberg Pharma achieved revenue of $7.7M and an EBITDA of -$20.6M.
Heidelberg Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Heidelberg Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.9M | XXX | $7.7M | XXX | XXX | XXX |
| Gross Profit | $11.9M | XXX | $5.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | -$28.2M | XXX | -$20.6M | XXX | XXX | XXX |
| EBITDA Margin | -238% | XXX | -268% | XXX | XXX | XXX |
| EBIT | -$29.1M | XXX | -$25.8M | XXX | XXX | XXX |
| EBIT Margin | -245% | XXX | -335% | XXX | XXX | XXX |
| Net Profit | -$29.3M | XXX | -$21.8M | XXX | XXX | XXX |
| Net Margin | -247% | XXX | -283% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Heidelberg Pharma's stock price is EUR 4 (or $4).
Heidelberg Pharma has current market cap of EUR 167M (or $187M), and EV of EUR 146M (or $164M).
See Heidelberg Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $164M | $187M | XXX | XXX | XXX | XXX | $-0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Heidelberg Pharma has market cap of $187M and EV of $164M.
Heidelberg Pharma's trades at 20.8x EV/Revenue multiple, and -7.5x EV/EBITDA.
Equity research analysts estimate Heidelberg Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Heidelberg Pharma has a P/E ratio of -6.4x.
See valuation multiples for Heidelberg Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $187M | XXX | $187M | XXX | XXX | XXX |
| EV (current) | $164M | XXX | $164M | XXX | XXX | XXX |
| EV/Revenue | 13.8x | XXX | 20.8x | XXX | XXX | XXX |
| EV/EBITDA | -5.8x | XXX | -7.5x | XXX | XXX | XXX |
| EV/EBIT | -5.6x | XXX | -6.1x | XXX | XXX | XXX |
| EV/Gross Profit | 13.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.4x | XXX | -8.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHeidelberg Pharma's last 12 month revenue growth is 12%
Heidelberg Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Heidelberg Pharma's rule of 40 is -183% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Heidelberg Pharma's rule of X is -208% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Heidelberg Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | -238% | XXX | -278% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -183% | XXX | -266% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -208% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 319% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 409% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heidelberg Pharma acquired XXX companies to date.
Last acquisition by Heidelberg Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Heidelberg Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Heidelberg Pharma founded? | Heidelberg Pharma was founded in 1997. |
| Where is Heidelberg Pharma headquartered? | Heidelberg Pharma is headquartered in Germany. |
| How many employees does Heidelberg Pharma have? | As of today, Heidelberg Pharma has 116 employees. |
| Is Heidelberg Pharma publicy listed? | Yes, Heidelberg Pharma is a public company listed on ETR. |
| What is the stock symbol of Heidelberg Pharma? | Heidelberg Pharma trades under HPHA ticker. |
| When did Heidelberg Pharma go public? | Heidelberg Pharma went public in 2006. |
| Who are competitors of Heidelberg Pharma? | Similar companies to Heidelberg Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Heidelberg Pharma? | Heidelberg Pharma's current market cap is $187M |
| What is the current revenue of Heidelberg Pharma? | Heidelberg Pharma's last 12 months revenue is $11.9M. |
| What is the current revenue growth of Heidelberg Pharma? | Heidelberg Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Heidelberg Pharma? | Current revenue multiple of Heidelberg Pharma is 13.8x. |
| Is Heidelberg Pharma profitable? | Yes, Heidelberg Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Heidelberg Pharma? | Heidelberg Pharma's last 12 months EBITDA is -$28.2M. |
| What is Heidelberg Pharma's EBITDA margin? | Heidelberg Pharma's last 12 months EBITDA margin is -238%. |
| What is the current EV/EBITDA multiple of Heidelberg Pharma? | Current EBITDA multiple of Heidelberg Pharma is -5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
